We compared the clinical parameters between the high CDC20 expression group and the low CDC20 expression group in MCL patients with PBMCs and tumor sections, and revealed that higher expression of CDC20 implied poor treatment response, worse tumor staging, increased risk of bone marrow involvement and dismal prognosis in MCL patients. Here, CDC20 is linked to neoplasm.